Application No.: 10/665,936

Amd. Dated:

Reply to Office Action mailed: 05/31/2006

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1, 6 and 17 have been amended;

Claims 2 and 21-54 have been canceled; and

New claims 56-72 have been added.

Listing of Claims:

 (Currently Amended) A device for the treatment of aneurysmal tissue, comprising:

at least one reservoir locatable implanted adjacent to an aneurysmal site;

at least one therapeutic agent within said reservoir; and

at least one carrier provided therewith-within said reservoir, where the carrier is capable of delivering delivers at least one therapeutic agent to said aneurysm site for the treatment of said aneurysmal tissue.

- (Canceled)
- 3. (Original) The device of claim 1, wherein carrier is a time release carrier.
- (Original) The device of claim 3, wherein the carrier and at least one therapeutic agent are formulated as a sheet, pellets, a sponge, a slab, a gel, capsules, microspheres, nanospheres, liquids or combinations thereof.
- (Original) The treatment device of claim 1, wherein the reservoir, when implanted, provides the at least one agent into the aneurysmal site.
- 6. (Currently Amended) The device of claim 1, wherein the reservoir e<u>r and the</u> carrier <u>individually comprise comprises</u> a synthetic biodegradable polymer, a synthetic biostable polymer, a natural polymer, an inorganic material or combinations thereof.

Application No.: 10/665,936

Amd. Dated:

Reply to Office Action mailed: 05/31/2006

7. (Original) The device of claim 6, wherein the biodegradable polymer is an aliphatic polyester, a poly(ortho ester), a poly(ester amide), a poly(ester urethane), a poly(ester anhydride), a poly(ester carbonate), a polyphosphazene, a polyarylate, a poly(ether ester), and/or combinations thereof.

- (Original) The device of claim 7, wherein the aliphatic polyester is poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), or poly(εcaprolactone) or co-polymers thereof.
- 9. (Original) The device of claim 6, wherein the biostable polymer is a polyolefin, a polyurethane, a fluorinated polyolefin, a chlorinated polyolefin, a polyamide, an acrylate polymer, an acrylamide polymer, a vinyl polymer, a polyacetal, a polycarbonate, a polyether, an aromatic polyester, a poly(ether ether ketone), a polysulfone, a silicone rubber, a thermoset, or a poly(ester imide) and/or combinations thereof.
- (Original) The device of claim 9, wherein the polymer is poly(butyl methacrylate), poly(methyl methacrylate), poly(ethylene-co-vinylacetate), or poly(ethylene-co-methylacetate) or co-polymers thereof.
- (Original) The device of claim 6, wherein the natural polymer is albumin, collagen, gelatin, hyaluronic acid, starch, alginate, pectin, cellulose and cellulose derivatives, casein, dextran, polysaccharides, or fibrinogen and/or combinations thereof.
- (Original) The device of claim 1, wherein the carrier comprises a synthetic biodegradable polymer, and the reservoir comprises a synthetic biostable polymer, a natural polymer, an inorganic material or combinations thereof.
- (Original) The device of claim 1, wherein the reservoir comprises a polymeric material.
- (Original) The device of claim 13, wherein the polymeric material is a polyolefin, a polyurethane, a silicone, a polyester, or a fluorinated polyolefin.
- (Original) The device of claim 1, wherein the at least one therapeutic agent is a matrix metalloproteinase (MMP) inhibitor, an antibiotic, a cyclooxygenase-2

Application No. : 10/665,936 Amd. Dated:

Reply to Office Action mailed: 05/31/2006

(COX-2) inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a glucocorticoid, a beta blocker, a nitric acid synthase (NOS) inhibitor, an antioxidant, an antibody, or a non-steroidal anti-inflammatory drug (NSAID).

- (Original) The device of claim 1, wherein at least one therapeutic comprises a combination of therapeutic agents.
- (Currently Amended) The device of-claim 15, wherein the reservoir is located adjacent a to said stent graft between the stent graft and the aneurysmal site.
- (Original) The device of claim 1, wherein the device is located inside the aneurysmal sac.
- (Original) The device of claim 1, wherein the device is located outside the aneurysmal sac.
- 20. (Original) A method of treating an aneurysm, comprising implanting the device of claim 1 in an aneurysmal site.
 - 21-54. (Canceled)
- 55. (New) The device of claim 1, further comprising a stent graft implanted at said aneurysm site.
- 56. (New) A method for the treating an aneurysm comprising: implanting a stent graft at an aneurysmal site; locating a reservoir remotely to said aneurysmal site; providing at least one carrier having at least one therapeutic agent dispersed therein within said reservoir; and
- delivering said carrier and said therapeutic agent from said reservoir to said aneurysmal site for the treatment of said aneurysmal tissue.
- (New) The method according to claim 56, wherein the providing step further comprises a time release carrier.

Application No.: 10/665,936 Amd. Dated:

Reply to Office Action mailed: 05/31/2006

(New) The method according to claim 56, wherein in the providing step 58. said carrier and at least one therapeutic agent are formulated as a gel, liquid or combinations thereof.

- 59 (New) The method according to claim 56, wherein in the locating and providing step the reservoir and the carrier comprise a synthetic biodegradable polymer. a synthetic biostable polymer, a natural polymer, an inorganic material or combinations thereof
- 60. (New) The method according to claim 59, wherein in the locating and providing step the biodegradable polymer is an aliphatic polyester, a poly(ortho ester), a poly(ester amide), a poly(ester urethane), a poly(ester anhydride), a poly(ester carbonate), a polyphosphazene, a polyarylate, a poly(ether ester), and/or combinations thereof
- (New) The method according to claim 60, wherein in the locating and providing step the aliphatic polyester is poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), or poly(ε-caprolactone) or co-polymers thereof.
- 62 (New) The method according to claim 59, wherein in the locating and providing step the biostable polymer is a polyolefin, a polyurethane, a fluorinated polyolefin, a chlorinated polyolefin, a polyamide, an acrylate polymer, an acrylamide polymer, a vinyl polymer, a polyacetal, a polycarbonate, a polyether, an aromatic polyester, a poly(ether ether ketone), a polysulfone, a silicone rubber, a thermoset, or a poly(ester imide) and/or combinations thereof.
- 63. (New) The method according to claim 62, wherein in the locating and providing step the polymer is poly(butyl methacrylate), poly(methyl methacrylate), poly(ethylene-co-vinylacetate), or poly(ethylene-co-methylacetate) or co-polymers thereof.
- 64 (New) The method according to claim 59, wherein in the locating and providing step the natural polymer is albumin, collagen, gelatin, hyaluronic acid, starch, alginate, pectin, cellulose and cellulose derivatives, casein, dextran, polysaccharides, or fibrinogen and/or combinations thereof.

Application No.: 10/665,936 Amd. Dated: Reply to Office Action mailed: 05/31/2006

- 65. (New) The method according to claim 56, wherein in the locating and providing step the carrier comprises a synthetic biodegradable polymer, and the reservoir comprises a synthetic biostable polymer, a natural polymer, an inorganic material or combinations thereof
- 66. (New) The method according to claim 56, wherein in the providing step the at least one therapeutic agent is a matrix metalloproteinase (MMP) inhibitor, an antibiotic, a cyclooxygenase-2 (COX-2) inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a glucocorticoid, a beta blocker, a nitric acid synthase (NOS) inhibitor, an antioxidant, an antibody, or a non-steroidal anti-inflammatory drug (NSAID).
- 67. (New) The method according to claim 56, wherein in the providing step the time release carrier comprises a combination of therapeutic agents.
- 68. (New) The method according to claim 56, wherein said delivery step further comprises a pump and tubing.
- 69. (New) The method according to claim 68, wherein in the delivery step the pump is a mechanical, electrical, or osmotic pump.
- 70. (New) The method according to claim 68, wherein in the delivery step a first end of the tubing is in communication with the pump and a second end of the tubing is located adjacent to the stent graft between the stent graft and the aneurysmal site.
- 71. (New) The method according to claim 56, wherein in the delivery step the therapeutic agent is delivered to the outer wall of the aneurysmal site.
- 72. (New) The method according to claim 56, wherein in the providing step said carrier is saline.